The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch ... an 'at home' collection service for people using growth hormone pens. "These pens are made from high-quality, long ...

In the growth disorders business, Novo Nordisk is also launching a new weekly growth hormone treatment ... like insulin pens. The company’s disease portfolio includes diabetes, obesity, and ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...

While Novo Nordisk has been operating in rare disease ... as well as drugs for growth hormone-related disorders such as Norditropin. More recently, Novo in December won a hard-fought FDA approval ...

Yet Novo Nordisk’s growth prospects are far from guaranteed ... with capacity for 100 million pens annually by 2025. With a market cap of $825 billion, it could become the next trillion-dollar ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...

That growth was driven primarily by ... which similarly employs the amylin pancreas hormone, led the stock higher last month. Novo Nordisk said Wednesday that it would conduct a further study ...